Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference.
about
Statins and its hepatic effects: Newer data, implications, and changing recommendationsA quick overview on some aspects of endocrinological and therapeutic effects of Berberis vulgaris LStatin-Associated Muscle Adverse Events: Update for cliniciansStatin associated hepatic adverse effects: a retrospective review from a regional hospital in sultanate of omanPCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemiaGenealogical analysis as a new approach for the investigation of drug intolerance heritability.The Effects of Melatonin on Elevated Liver Enzymes during Statin Treatment.Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.Anti-angiogenic treatment strategies for the therapy of endometriosis.Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients.Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial.Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4.Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: A double blind, placebo controlled randomized trialStatin Safety in Chinese: A Population-Based Study of Older AdultsLipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk.Treatment Options for Statin-Associated Muscle Symptoms.AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism.Nutrition of the critically ill — a 21st-century perspective.Statin tolerability: In defence of placebo-controlled trials.Molecular mechanisms of statin intoleranceSLCO1B1 Polymorphisms and Statin-Induced Myopathy.Management of statin intoleranceIntolerance to statins: mechanisms and management.Nutrition of the critically ill - emphasis on liver and pancreasPotential for statins in the chemoprevention and management of hepatocellular carcinoma.Critical review of non-statin treatments for dyslipoproteinemia.Addressing statin adverse effects in the clinic: the 5 Ms.Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?Muscle- and skeletal-related side-effects of statins: tip of the iceberg?Statins and Nonadherence: Should We RELATE Better?Immune-mediated statin myopathy.Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin.Statin-related aminotransferase elevation according to baseline aminotransferases level in real practice in Korea.Statins for aortic valve stenosis.Analysis and comparison of statin prescription patterns and outcomes according to clinical department.Intervention Effects of Atorvastatin Combined with Panax notoginseng Saponins on Rats with Atherosclerosis Complicated with Hepatic Injury.Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study.Atorvastatin Induced Adverse Drug Reactions among South Indian Tamils.Clinical evaluation of rosuvastatin in heart transplant patients with hypercholesterolemia and therapeutic failure of other statin regimens: short-term and long-term efficacy and safety results.
P2860
Q26767065-1752B330-C1D3-4BA7-84D0-633246A0FE33Q26773570-FF8E7BB9-EAA1-461E-9BDF-74071C700859Q28074144-45EBF7AE-E99D-49F1-B6A9-C0895124C521Q28654581-37B2C64A-9637-422A-8E7F-B620B1FFB36CQ30234612-D219914C-5AFE-49E2-8A06-47DCFA0D1567Q33711391-509FA837-BC76-43F9-B6A3-54071182A2F1Q33765249-BEC7E8B3-568C-4903-A1C5-BBAA05FB7234Q33786661-E70D66C3-58A9-456C-8B3D-9CE4DB1B7CB5Q33808620-4D367D19-D015-422B-A237-B1431069F1F4Q34283036-5C03550F-F7EE-4576-8D0C-7761955EDBC8Q34683910-732203AC-195B-491E-BAB9-9812E1DA005FQ34834399-C21E3A19-87A5-4714-BC35-7A03A1230BCCQ35088420-2F90AAB5-83D2-470F-B619-0D69A963DE59Q35189508-BF92F666-B234-45CA-9424-CE6612E4FC5CQ35949456-2A1270A7-E257-4E04-9BCB-F26EAB08112AQ36103282-A538F9F5-FCBB-487C-A053-153B504CB1FDQ36294394-774A5FAC-101E-4FA8-855F-58E29E83B607Q36462041-BF7D2658-A8E5-4287-ABDE-74BAD0603474Q36607663-3157BB09-931A-4984-A7B9-C0DCB1AE4833Q36841934-BB5C6E48-4036-4297-8E87-F79DCCEAB62BQ36958324-AC1696D4-0D46-4734-A43E-97A2D6E18AEEQ37410969-2877AB33-C818-4299-A9B3-4B621816C401Q37414000-12DB6393-0C2C-4F4B-A9B2-2B8A74DC881DQ37577161-4B8C6BB5-DF70-40B8-B3B8-9D6E4848F491Q37584566-811C2CE0-1E13-4133-A417-5CE691554E46Q38030991-A97B1B90-6473-44BF-B103-DA48767E3192Q38186099-E8B9F50D-392E-499A-93F7-EB7A6D5D66DCQ38207488-80C2771E-F39A-4231-A370-6B40FF5DBF20Q38228757-32B868C6-CC1C-474B-9005-D0E8B7950D40Q38250622-BA5CF83B-26E7-4B7F-948F-9991A10CB84EQ38398011-843F7162-6CDB-403E-99DD-54AE7642A5B2Q38619946-57FE2D33-1730-4622-81FA-026DCD50A5FAQ38819959-A423BA3B-8164-4269-B2B4-B234CA502C89Q38890066-F3EDA878-1F7C-45E3-85E4-C7D2F1CAB559Q38946280-21788093-5769-4B6C-805B-A8E7FFB202DDQ40081703-5479ACCD-5952-4F29-B018-DA9AA6BFD926Q41340082-2AC66FD8-8E0C-4820-92EA-4737793DA26CQ44436736-3B52090A-6A8E-41F0-A0BC-757C44DAA3FFQ48002829-A61486CC-7A2B-4046-BA7F-76DE9BCE56E7Q48203172-E251E3EF-B9B0-4549-BF52-B05CB3FF5660
P2860
Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Diagnosis, prevention, and man ...... ng Group Consensus Conference.
@ast
Diagnosis, prevention, and man ...... ng Group Consensus Conference.
@en
Diagnosis, prevention, and man ...... ng Group Consensus Conference.
@nl
type
label
Diagnosis, prevention, and man ...... ng Group Consensus Conference.
@ast
Diagnosis, prevention, and man ...... ng Group Consensus Conference.
@en
Diagnosis, prevention, and man ...... ng Group Consensus Conference.
@nl
altLabel
Diagnosis, prevention, and man ...... ing Group Consensus Conference
@en
prefLabel
Diagnosis, prevention, and man ...... ng Group Consensus Conference.
@ast
Diagnosis, prevention, and man ...... ng Group Consensus Conference.
@en
Diagnosis, prevention, and man ...... ng Group Consensus Conference.
@nl
P2093
P50
P1476
Diagnosis, prevention, and man ...... ng Group Consensus Conference.
@en
P2093
David Fitchett
Dominic Ng
G B John Mancini
Janet Pope
Jean Bergeron
Jiri Frohlich
Steven Baker
P304
P356
10.1016/J.CJCA.2011.05.007
P407
P577
2011-09-01T00:00:00Z